Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US ...

German pharma company Merck is buying US biotech SpringWorks Therapeutics for $3.9B. SpringWorks makes medicines for cancer ...

Merck KGaA (Merck) has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire ...

Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the ...

Merck KGaA acquires SpringWorks Therapeutics for $3.9B to enhance its cancer drug portfolio, boosting revenue growth and ...

Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to add ...

Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc.

Two months after confirming “advanced talks” for a potential merger, Stamford-based SpringWorks Therapeutics Inc. on Monday ...

Planned acquisition will strengthen the US presence of Merck Healthcare and expand reach of SpringWorks’ therapeutic ...

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said. An announcement ...

The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.

FRANKFURT (REUTERS) -German healthcare and materials group Merck KGaA said on Monday it struck a deal to acquire U.S. biotech ...